VivoSeq
Cardiovascular

Chronic Coronary Syndrome

0

Pipeline Programs↗

7

Active Trials↗

0

Companies Involved↗

Chronic Coronary Syndrome is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Unknown status3 · 27%
Recruiting3 · 27%
Not yet recruiting2 · 18%
Completed1 · 9%
Active, not recruiting1 · 9%
Enrolling by invitation1 · 9%

Clinical Trials

Trial Activity

11 trials

Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
Recruiting·—·N/A·NCT06896708·766 enrolled
Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome
Recruiting·SShandong First Medical University·Phase 4·NCT06171061·1,200 enrolled
Carotid Ultrasound Vs Computed Tomography (CT) Coronary Calcium Scoring to Reclassify Symptomatic Patients With Suspected Chronic Coronary Syndrome Using Risk Factor Clinical Likelihood for Obstructive Coronary Artery Disease
Recruiting·LLondon North West Healthcare NHS Trust·Preclinical·NCT07696533·225 enrolled
Chronic Coronary Syndrome Real Practice and Guidelines
Active, not recruiting·—·N/A·NCT06684366·300 enrolled
A Prospective muLticEnter Registry in chrONic coronARy synDrOme
Not yet recruiting·UUniversity of Roma La Sapienza·N/A·NCT06198673·1,000 enrolled
Assessment of GARP Expression in Acute and Chronic Coronary Syndrome
Not yet recruiting·UUniversité Catholique de Louvain·N/A·NCT07384910·600 enrolled
Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients
Enrolling by invitation·TThe Society of Prevention and Awareness of Cardiovascular Diseases·N/A·NCT06808321·800 enrolled
Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
Completed·—·N/A·NCT04753372·645 enrolled
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
Unknown status·NNova Scotia Health Authority·Phase 4·NCT05116995·30 enrolled
the Role of Ivabradine in Causing AF in Patients With Chronic Coronary Syndrome
Unknown status·—·N/A·NCT05168189·180 enrolled
Effect of Yangxinshi Tablet on Exercise Tolerance in Patients With Chronic Coronary Syndrome（MET STUDY）
Unknown status·—·Phase 4·NCT05978089·120 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)